Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00749320 · ClinicalTrials.gov registry record · NA
Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)
A NA study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT00749320 is a NA study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 32 participants.
The verdict
NCT00749320, a NA study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to assess magnetic resonance imaging (MRI) as a tool to track tumor growth for renal cell carcinoma while the participant is receiving clinical treatment therapy with sunitinib or pazopanib. An MRI is a sophisticated type of scan that uses powerful magnets to make clearer images or to focus on detailed medical information in the participants abdomen and pelvis. This imaging done for this study will use the ASL MRI technique that allows us to see blood flow changes which possibly may indicated tumor growth.
Interventions
- OTHER Arterial Spin Labeling Magnetic Resonance Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2008-09 |
| Est. Completion | 2019-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00749320
The ClinicalTrials.gov registry entry for NCT00749320 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Arterial Spin Labeling Magnetic Resonance Imaging is the first listed.
NCT00749320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00749320 about?
NCT00749320 is a clinical study titled "Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)". The purpose of this study is to assess magnetic resonance imaging (MRI) as a tool to track tumor growth for renal cell carcinoma while the participant is receiving clinical treatment therapy with sunitinib or pazopanib. An MRI is a sophisticated type of scan that uses powerful magnets to make cleare...
What is the current status of trial NCT00749320?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2008-09. Estimated completion is 2019-12.
What interventions are being tested in trial NCT00749320?
The interventions under investigation include: Arterial Spin Labeling Magnetic Resonance Imaging (OTHER).
Who is sponsoring clinical trial NCT00749320?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.